Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Levy, 2012, Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study, Lancet Infect Dis, 12, 919, 10.1016/S1473-3099(12)70239-6
Wagenlehner, 2008, Therapeutic challenges of urosepsis, Eur J Clin Invest, 38, 45, 10.1111/j.1365-2362.2008.02008.x
Cek, 2014, Healthcare-associated urinary tract infections in hospitalized urological patients-a global perspective: results from the GPIU studies 2003–2010, World J Urol, 32, 1587, 10.1007/s00345-013-1218-9
Sievert, 2013, Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010, Infect Control Hosp Epidemiol, 34, 1, 10.1086/668770
Tandogdu, 2014, Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study, World J Urol, 32, 791
Wagenlehner, 2012, Epidemiology, treatment and prevention of healthcare-associated urinary tract infections, World J Urol, 30, 59, 10.1007/s00345-011-0757-1
Lee, 2011, Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis, J Infect, 62, 159, 10.1016/j.jinf.2010.10.009
Yang, 2010, Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections, J Microbiol Immunol Infect, 43, 194, 10.1016/S1684-1182(10)60031-X
Spoorenberg, 2014, Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay, Clin Infect Dis, 58, 164, 10.1093/cid/cit688
Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2
Farrell, 2013, Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012), Antimicrob Agents Chemother, 57, 6305, 10.1128/AAC.01802-13
Sader, 2014, Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012), J Infect, 69, 266, 10.1016/j.jinf.2014.04.004
Grabe
Hooton, 2010, Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America, Clin Infect Dis, 50, 625, 10.1086/650482
Peterson, 2008, A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis, Urology, 71, 17, 10.1016/j.urology.2007.09.002
Sandberg, 2012, Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial, Lancet, 380, 484, 10.1016/S0140-6736(12)60608-4
2012
Mehrotra, 2000, Minimum risk weights for comparing treatments in stratified binomial trials, Stat Med, 19, 811, 10.1002/(SICI)1097-0258(20000330)19:6<811::AID-SIM390>3.0.CO;2-Z
Wiens, 2003, Testing for interaction in studies of noninferiority, J Biopharm Stat, 13, 103, 10.1081/BIP-120017729
Magill, 2014, Multistate point-prevalence survey of health care-associated infections, N Engl J Med, 370, 1198, 10.1056/NEJMoa1306801
Bouchillon, 2012, Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009–2010, Open Microbiol J, 6, 74, 10.2174/1874285801206010074
Bouchillon, 2013, Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2011, Clin Ther, 35, 872, 10.1016/j.clinthera.2013.03.022
Nicolle, 2005, Complicated urinary tract infection in adults, Can J Infect Dis Med Microbiol, 16, 349, 10.1155/2005/385768
Rafat, 2013, Levofloxacin for the treatment of pyelonephritis, Expert Opin Pharmacother, 14, 1241, 10.1517/14656566.2013.792805
Doi, 2013, Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States, Clin Infect Dis, 56, 641, 10.1093/cid/cis942
Naber, 2009, Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis, Antimicrob Agents Chemother, 53, 3782, 10.1128/AAC.00837-08
Cox, 1989, Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections, Urology, 34, 322, 10.1016/0090-4295(89)90335-X
Nicolle, 1994, Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole, Antimicrob Agents Chemother, 38, 1368, 10.1128/AAC.38.6.1368
Redman, 2010, Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis, J Chemother, 22, 384, 10.1179/joc.2010.22.6.384
Cox, 1995, A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients, Clin Infect Dis, 21, 86, 10.1093/clinids/21.1.86
Corey, 2010, Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection, Clin Infect Dis, 51, 641, 10.1086/655827